OncoMatch/Clinical Trials/NCT06802315
Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)
Is NCT06802315 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cyclophosphamide (CTX) and Fludarabine (Fludara) for acute myeloid leukemia, relapsed, adult.
Treatment: Cyclophosphamide (CTX) · Fludarabine (Fludara) · Busulfan (conditioning for ALLO Transplant) — The study is a Phase II clinical trial. Patients will receive intensity-modulated total marrow irradiation (TMI) at a dose of 9 Gray (Gy) with standard myeloablative fludarabine intravenous (IV) and targeted busulfan (FluBu4) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT). Graft-versus-host disease (GVHD) prophylaxis will include Cyclophosphamide on Day +3 and +4, tacrolimus, and mycophenolate mofetil.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Myelodysplastic Syndrome
Biomarker criteria
Allowed: ASXL1 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: BCOR poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: EZH2 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: RUNX1 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: SF3B1 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: SRSF2 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: STAG2 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: U2AF1 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: ZRSR2 poor risk molecular feature
Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2
Allowed: KMT2A (MLL) rearrangement (MLL rearrangement except t(9;11))
Poor-risk cytogenetics: MLL rearrangement with the exception of t(9;11)
Prior therapy
Cannot have received: radiation therapy
Exception: to >20% of bone marrow-containing areas
Patients previously received radiation to >20% of bone marrow-containing areas
Lab requirements
Kidney function
creatinine clearance <30ml/min [excluded]
Liver function
bilirubin > 2.0 mg/dl (unless due to gilbert's syndrome or hemolysis), and alt and ast > 5 x uln [excluded]
Cardiac function
left ventricular ejection fraction < 50% [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Illinois Cancer Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify